Correlation between PPAR-α methylation level in peripheral blood and atherosclerosis of NAFLD patients with DM

Ju,Jianghua; Huang,Qingxian; Sun,Jing; Zhao,Xiaoyun; Guo,Xiuli; Jin,Yongcheng; Ma,Wenjie; Wang,Wenhui

doi:10.3892/etm.2018.5730

Correlation between PPAR-α methylation level in peripheral blood and atherosclerosis of NAFLD patients with DM

Authors:
- Jianghua Ju
- Qingxian Huang
- Jing Sun
- Xiaoyun Zhao
- Xiuli Guo
- Yongcheng Jin
- Wenjie Ma
- Wenhui Wang
View Affiliations

Affiliations: Department of Endocrinology, Qilu Hospital of Shandong University, Qingdao, Shandong 266035, P.R. China
Published online on: January 10, 2018 https://doi.org/10.3892/etm.2018.5730
Pages: 2727-2730
Copyright: © Ju et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

We investigated the correlation between the methylation levels of peroxisome proliferator-activated receptor-α (PPAR-α) in the peripheral blood and atherosclerosis in patients with nonalcoholic fatty liver disease (NAFLD) with diabetes mellitus (DM). A total of 50 normal subjects (group N) and 50 NAFLD patients with DM (group M) were selected at Qilu Hospital of Shandong University. The levels of total cholesterol (TC), triglyceride (TG), high-density lipoprotein (HDL) and low-density lipoprotein (LDL) in groups N and M were detected. The mRNA and protein expressions of PPAR-α in groups N and M were detected using reverse transcription polymerase chain reaction (PCR) and immunofluorescence. The differences in expression of PPAR-α in group N and M and the correlation between PPAR-α methylation level and atherosclerosis were analyzed using SPSS17.0 statistical software. TC, TG, HDL and LDL in groups N and M were significantly different (P<0.01). Hematoxylin and eosin staining showed that the histopathological damage was severe in group M. PCR and immunofluorescence showed that PPAR-α was significantly higher in N than in group M (P<0.01). The abnormal expression of PPAR-α is closely related to atherosclerosis, indicating that the correlation between PPAR-α methylation levels in peripheral blood and atherosclerosis of NAFLD patients with DM can provide a new direction of diagnosis and treatment.

View Figures

View References

1	Vernon G, Baranova A and Younossi ZM: Systematic review: The epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 34:274–285. 2011. View Article : Google Scholar : PubMed/NCBI
2	Charlton M: Nonalcoholic fatty liver disease: A review of current understanding and future impact. Clin Gastroenterol Hepatol. 2:1048–1058. 2004. View Article : Google Scholar : PubMed/NCBI
3	Lazo M, Hernaez R, Bonekamp S, Kamel IR, Brancati FL, Guallar E and Clark JM: Non-alcoholic fatty liver disease and mortality among US adults: Prospective cohort study. BMJ. 343:d68912011. View Article : Google Scholar : PubMed/NCBI
4	Nestel PJ and Mensink RP: Perspective: Nonalcoholic fatty liver disease and cardiovascular risk. Curr Opin Lipidol. 24:1–3. 2013. View Article : Google Scholar : PubMed/NCBI
5	Bhatia LS, Curzen NP, Calder PC and Byrne CD: Non-alcoholic fatty liver disease: A new and important cardiovascular risk factor. Eur Heart J. 33:1190–1200. 2012. View Article : Google Scholar : PubMed/NCBI
6	Barger PM and Kelly DP: PPAR signaling in the control of cardiac energy metabolism. Trends Cardiovasc Med. 10:238–245. 2000. View Article : Google Scholar : PubMed/NCBI
7	Lee SST, Pineau T, Drago J, Lee EJ, Owens JW, Kroetz DL, Fernandez-Salguero PM, Westphal H and Gonzalez FJ: Targeted disruption of the α isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol Cell Biol. 15:3012–3022. 1995. View Article : Google Scholar : PubMed/NCBI
8	Targher G, Day CP and Bonora E: Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med. 363:1341–1350. 2010. View Article : Google Scholar : PubMed/NCBI
9	Pacana T and Fuchs M: The cardiovascular link to nonalcoholic fatty liver disease: A critical analysis. Clin Liver Dis. 16:599–613. 2012. View Article : Google Scholar : PubMed/NCBI
10	Lu H, Liu H, Hu F, Zou L, Luo S and Sun L: Independent association between nonalcoholic fatty liver disease and cardiovascular disease: A systematic review and meta-analysis. Int J Endocrinol. 2013:1249582013. View Article : Google Scholar : PubMed/NCBI
11	Villanova N, Moscatiello S, Ramilli S, Bugianesi E, Magalotti D, Vanni E, Zoli M and Marchesini G: Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology. 42:473–480. 2005. View Article : Google Scholar : PubMed/NCBI
12	Akabame S, Hamaguchi M, Tomiyasu K, Tanaka M, Kobayashi-Takenaka Y, Nakano K, Oda Y and Yoshikawa T: Evaluation of vulnerable coronary plaques and non-alcoholic fatty liver disease (NAFLD) by 64-detector multislice computed tomography (MSCT). Circ J. 72:618–625. 2008. View Article : Google Scholar : PubMed/NCBI
13	Djouadi F, Weinheimer CJ, Saffitz JE, Pitchford C, Bastin J, Gonzalez FJ and Kelly DP: A gender-related defect in lipid metabolism and glucose homeostasis in peroxisome proliferator-activated receptor α-deficient mice. J Clin Invest. 102:1083–1091. 1998. View Article : Google Scholar : PubMed/NCBI
14	Aoyama T, Peters JM, Iritani N, Nakajima T, Furihata K, Hashimoto T and Gonzalez FJ: Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor α (PPARalpha). J Biol Chem. 273:5678–5684. 1998. View Article : Google Scholar : PubMed/NCBI
15	Leone TC, Weinheimer CJ and Kelly DP: A critical role for the peroxisome proliferator-activated receptor alpha (PPARalpha) in the cellular fasting response: The PPARalpha-null mouse as a model of fatty acid oxidation disorders. Proc Natl Acad Sci USA. 96:pp. 7473–7478. 1999; View Article : Google Scholar : PubMed/NCBI
16	Kersten S, Seydoux J, Peters JM, Gonzalez FJ, Desvergne B and Wahli W: Peroxisome proliferator-activated receptor α mediates the adaptive response to fasting. J Clin Invest. 103:1489–1498. 1999. View Article : Google Scholar : PubMed/NCBI
17	Moore LD, Le T and Fan G: DNA methylation and its basic function. Neuropsychopharmacology. 38:23–38. 2013. View Article : Google Scholar : PubMed/NCBI
18	Niculescu MD and Zeisel SH: Diet, methyl donors and DNA methylation: Interactions between dietary folate, methionine and choline. J Nutr. 132:2333–2335. 2002. View Article : Google Scholar
19	Oakes CC, La Salle S, Robaire B and Trasler JM: Evaluation of a quantitative DNA methylation analysis technique using methylation-sensitive/dependent restriction enzymes and real-time PCR. Epigenetics. 1:146–152. 2006. View Article : Google Scholar : PubMed/NCBI
20	Contreras AV, Torres N and Tovar AR: PPAR-α as a key nutritional and environmental sensor for metabolic adaptation. Adv Nutr. 4:439–452. 2013. View Article : Google Scholar : PubMed/NCBI